Pfizer, OncoImmune in Immuno-Oncology Licensing Pact
By
Pfizer has signed an exclusive option and license agreement with OncoImmune, a clinical-stage biopharmaceutical company based in Rockville, Maryland, for OncoImmune’s immuno-oncology drug candidate, ONC-392, a differentiated, preclinical anti-cytotoxic T-lymphocyte…